SCHEMBL642883

SCHEMBL642883

COC(=O)C1(N(C)S(=O)(=O)c2ccc(OC)cc2)CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.43
MMP3 P08254 3/20 0.42
KEAP1 Q14145 2/20 0.42
NFE2L2 Q16236 1/20 0.42
CYP2C9 P11712 1/20 0.42
MMP1 P03956 3/20 0.41
MMP8 P22894 3/20 0.41
MMP2 P08253 2/20 0.41
MMP9 P14780 2/20 0.41
MMP13 P45452 2/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
MMP7 P09237 2/20 0.41
POLB P06746 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MMP12 P39900 1/20 0.41
MAPT P10636 1/20 0.41
TSHR P16473 1/20 0.41
HTT P42858 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL644793 0.88 PLAU (0.46) ALDH1A1KEAP1NFE2L2POLBSMN1; SMN2
SCHEMBL6504803 0.83 ADAM17 (0.54) MMP1MMP8MMP2MMP9MMP13
SCHEMBL16013298 0.80 KMT2A (0.48) ALDH1A1MMP1CA1CA2SMN1; SMN2
SCHEMBL6291043 0.77 MMP13 (0.52) ALDH1A1MMP3KEAP1NFE2L2CYP2C9
SCHEMBL643982 0.73 MMP1 (0.55) ALDH1A1MMP3MMP1MMP8MMP2
SCHEMBL6291117 0.73 KDM4E (0.47) ALDH1A1MMP3KEAP1NFE2L2CYP2C9
SCHEMBL10458558 0.71 CES2 (0.48) ALDH1A1CA1CA2MAPTHTR2A
SCHEMBL5852079 0.71 PLAU (0.49) ALDH1A1KEAP1NFE2L2SMN1; SMN2MAPT
SCHEMBL7348771 0.70 BMP1 (0.53) MMP1MMP9MMP13
SCHEMBL6506927 0.70 ADAM17 (0.59) MMP1MMP8MMP2MMP9MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119633-B2 N-{2-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-2-oxo-ethoxy]-ethyl}-N-ethyl-4-methoxy-2,3,6-trimethyl-phenylsulfonamide; condensing the N-carboxyalkyl phenylsulfonamide with the substituted piperidine; bradykinin receptor antagonists; analgesics; antidiabetics; angiogenesis inhibitors; rheumatic diseases GRUENENTHAL GMBH (DE) 2012-02-21 US disclosed
EP-2150530-B1 SUBSTITUTED SULFONAMIDE DERIVATIVES GRUENENTHAL GMBH (DE) 2011-10-26 EP disclosed
EP-2150530-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2010-02-10 EP disclosed
US-20080312231-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2008-12-18 US disclosed
WO-2008131947-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312231-A1 Substituted Sulfonamide Compounds SULT2A1, SULT1A1, SCN1A ALDH1A1 511/4885MMP3 2659/4885KEAP1 2428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.